Table 2.
Univariate and multivariate analyses for OS in HBV-associated hepatocellular carcinoma patients who had known baseline HBV DNA levels
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P value | HR (95% CI) | P value | HR (95% CI) | |
| Group (≥ 500 IU/mL versus < 500 IU/mL) | 0.013 | 0.37 (0.17–0.81) | 0.59 | 0.77 (0.29–2.02) |
| Antiviral treatment (no versus yes) | 0.010 | 0.27 (0.10–0.73) | 0.002 | 0.18 (0.06–0.52) |
| Age (years) (> 60 versus ≤ 60) | 0.098 | 2.26 (0.86–5.94) | ||
| Gender (female versus male) | 0.98 | 1.01 (0.31–3.37) | ||
| Alcohol consumption (yes versus no) | 0.074 | 2.05 (0.93–4.52) | ||
| ECOG performance status (0 + 1 versus 2) | 0.00 | 8.68 (3.20–23.58) | 0.00 | 11.87 (3.96–35.57) |
| AFP ng/mL (≥ 1210 versus < 1210) | 0.11 | 0.55 (0.26–1.15) | ||
| HBeAg status (positive versus negative) | 0.001 | 0.24 (0.10–0.56) | 0.21 | 0.52 (0.19–1.44) |
| ALBI grade (1versus 2 + 3) | 0.007 | 3.21 (1.37–7.51) | 0.54 | 1.41 (0.48–4.14) |
| Child–Pugh stage (A versus B) | 0.21 | 1.68 (0.74–3.77) | ||
| BCLC Stage (0 + A versus B + C) | 0.12 | 5.00 (0.68–36.90) | ||
| Liver cirrhosis (yes versus no) | 0.22 | 0.59 (0.25–1.37) | ||
| Total bilirubin, µmol/L (< 34 versus ≥ 34) | 0.63 | 1.30 (0.45–3.74) | ||
| Albumin, g/L (≤ 35 versus > 35) | 0.001 | 0.29 (0.14–0.60) | 0.075 | 0.44 (0.18–1.09) |
| ALT, U/L (≤ 40 versus > 40) | 0.042 | 2.15 (1.03–4.52) | 0.94 | 1.03 (0.45–2.39) |
| Vascular invasion (yes versus no) | 0.001 | 0.30 (0.14–0.61) | 0.00 | 0.23 (0.10–0.52) |
| Tumor size, cm (≤ 5 versus > 5) | 0.14 | 0.58 (0.29–1.20) | ||
| Tumor number (Multiple versus Single) | 0.13 | 0.33 (0.08–1.39) | ||
| Extrahepatic metastasis (yes versus no) | 0.12 | 0.56 (0.27–1.16) | ||
| Treatment modality (mono versus combined) | 0.41 | 0.63 (0.21–1.87) | ||